RE:RE:News on Globe and Mail
If Bioniche plays their cards right, they too will soon be an early stage, pre clinical, one shot, over dilluted, VP laden, partner-less micro cap Biotech with depleted cash, no revenue, high burn and too many staff.
Throw in a 60 million dollar white elephant and an unwanted cattle vaccine and you have the makings of a Biotech set to soar as well.
All is good, at least they will still have that "No Risk" cancer drug!